BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/21/2026 9:00:12 AM | Browse: 3 | Download: 9
 |
Received |
|
2026-01-16 07:04 |
|
Peer-Review Started |
|
2026-01-16 07:04 |
|
First Decision by Editorial Office Director |
|
2026-01-22 08:32 |
|
Return for Revision |
|
2026-01-22 08:32 |
|
Revised |
|
2026-01-29 11:24 |
|
Publication Fee Transferred |
|
2026-02-02 02:44 |
|
Second Decision by Editor |
|
2026-03-06 02:34 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-06 07:08 |
|
Articles in Press |
|
2026-03-06 07:08 |
|
Edit the Manuscript by Language Editor |
|
2026-03-07 10:47 |
|
Typeset the Manuscript |
|
2026-03-31 12:54 |
|
Publish the Manuscript Online |
|
2026-04-21 09:00 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
New breakthroughs and future trends in renal cell carcinoma therapy from the European Society for Medical Oncology 2025
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhen-Yu Liu, Yu Zhou, Fu-Han Zhao, Lin Wang, Tie-Jun Pan and Lei Gao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Natural Science Foundation of Hubei Province |
No. 2023AFB498 |
| Natural Science Foundation Exploration Plan (Morning Light Plan) of Wuhan City |
No. 2024040801020363 |
| Postdoctoral Scientific Research Foundation, General Hospital of Central Theater Command |
No. 20230102KY39 |
|
| Corresponding Author |
Lei Gao, Professor, Department of Urology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuluo Road, Zhongnan Street, Wuhan, Hubei, Wuhan 430070, Hubei Province, China. 511376424@qq.com |
| Key Words |
Renal cell carcinoma; Precision medicine; European Society for Medical Oncology 2025; Immunotherapy; Biomarkers |
| Core Tip |
This timely review synthesizes pivotal advances in renal cell carcinoma management presented at the European Society for Medical Oncology 2025 Congress. It highlights the shift towards precision medicine, evidenced by risk-stratified adjuvant immune checkpoint inhibitor therapy, promising short-course neoadjuvant immune checkpoint inhibitor strategies, and the evolution towards triple-combination regimens in advanced disease. A parallel focus is the critical development of predictive biomarkers - from molecular classifiers to artificial intelligence-based pathology tools - to guide individualized treatment selection and optimize outcomes across the disease spectrum, marking a decisive move beyond a one-size-fits-all therapeutic approach. |
| Publish Date |
2026-04-21 09:00 |
| Citation |
Liu ZY, Zhou Y, Zhao FH, Wang L, Pan TJ, Gao L. New breakthroughs and future trends in renal cell carcinoma therapy from the European Society for Medical Oncology 2025. World J Clin Oncol 2026; 17(4): 118954 |
| URL |
https://www.wjgnet.com/2218-4333/full/v17/i4/118954.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v17.i4.118954 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
